Shelf-stable formulation of glucagon-like peptide-1
CA 2358107 C · Owner: Pekar, Allen Howard · Inventors: Pekar, Allen Howard; Brader, Mark Laurence
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Glucagon-like peptide-1 (GLP-1) has been shown to be useful in the treatment of diabetes. The invention encompasses a shelf stable formulation that comprises a therapeutically effective amount of GLP-1 a pharmaceutically , acceptable preservative and a tonicity modifier, and that has a pH between about 8.2 to about 8.8.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 21, 1999 and granted August 23, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 21, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 21, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.